Biolipox completes aquisition from Inflazyme

Biolipox – with whom Orexo has reached an agreement under which Orexo will aquire Biolipox – completes the previously announced acquisition of the main part of the Canadian biopharma company Inflazymes research- and development assets.

For detailed information, visit

For more information, please contact:

Torbjörn Bjerke, President and CEO, Biolipox AB
+46 (0)708-66 19 90, e-mail:

Claes Wenthzel, Executive VP and CFO, Orexo AB
+46 (0)18 780 88 44, +46 (0)708-62 01 22 , e-mail: